Educational use only. Check doses against the product monograph and local protocols.

ESAs and IV iron

in review 4 min read Updated 2026-11-01
ESAs and IV iron in CKD

Iron first (thresholds by dialysis status), then an ESA if Hb stays low and symptoms or transfusion risk justify it. ESA preferred over HIF-PHI (KDIGO 2026, 2D). Keep Hb <115 g/L (1D). General iron-deficiency formulations and reactions → iron deficiency.

mechanism

ESAs: recombinant erythropoietin or analogues. HIF-PHIs: oral; stabilise HIF → endogenous EPO and better iron handling.


dosing

iron — KDIGO 2026

non-dialysis / PDhaemodialysis
start ifferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25%ferritin ≤500 + TSAT ≤30%
routeoral or IV (preference, severity, cost)IV, proactive (PIVOTAL (2019))
hold ifferritin >700 or TSAT ≥40%same
monitorHb, ferritin, TSAT every 3 monthsevery 1–3 months
IV ironmax single doseCKD notes
iron sucrose200 mg (non-dialysis), 400 mg (PD)1 g needs 5 × 200 mg over 5 weeks
ferric derisomaltose1000 mg or 20 mg/kgfull dose in one sitting
ferric carboxymaltose750 mg (FDA) / 1000 mg (EMA)hypophosphataemia, especially early CKD and transplant
ferric gluconate125 mgweekly doses
ferumoxytol510 mgsingle sitting
  • Switch oral → IV after 1–3 months of poor response or intolerance
  • No routine test dose or steroid/antihistamine premedication; give only where hypersensitivity can be managed
  • Hold during systemic infection
  • Ferric citrate used as a phosphate binder raises iron indices → count it in iron decisions (KDOQI)
  • Profound iron deficiency without anaemia (ferritin <30 + TSAT <20%), especially with heart failure → consider treating (KDIGO, KDOQI) → iron deficiency

ESAs — KDIGO 2026

agentnon-dialysis startdialysis start
epoetin alfa/beta≈50 U/kg once or twice weekly (or up to 100 U/kg every 2 weeks)50–100 U/kg 3× weekly
darbepoetin0.45 µg/kg weekly or 40–100 µg every 2–4 weeks0.45 µg/kg weekly or 0.75 µg/kg every 2 weeks
methoxy-PEG epoetin beta0.6 µg/kg every 2 weeks or 1.5 µg/kg monthly0.6 µg/kg every 2 weeks
  • Start on dialysis when Hb ≤90–100 g/L. Non-dialysis: individualise to symptoms and transfusion risk
  • Subcutaneous if not on HD; HD → IV or SC
  • Check Hb every 2–4 weeks after a start or dose change. Change the dose no more often than 4-weekly. Hb rise >10 g/L in 2–4 weeks → reduce 25–50% (reduce rather than stop — KDOQI). Maintenance: Hb at least every 3 months
  • Dialysis titration: Hb rise <10 g/L at 4 weeks → epoetin +25 U/kg/dose (darbepoetin +25%). Rise >20 g/L → reduce

key points

  • Reversible causes first: iron, B12/folate, infection/inflammation, hyperparathyroidism, inadequate dialysis, hypothyroidism, haemolysis, marrow disease
  • Lowest dose that meets the goal. Aiming for normal Hb harms: TREAT (2009) (darbepoetin to Hb 130, T2D + CKD) — no CV or kidney benefit, more strokes; CHOIR (2006) (Hb 135 vs 113) — more death/CV events. Practical range ~100–110 g/L (KDOQI)
  • Reasonable to suspend during admission for stroke, access thrombosis or VTE; restart individualised. Falling Hb on an ESA → reduce rather than hold
  • Transfusion: decide on symptoms, not a Hb number
  • Cancer (active or history) → shared decision; aim only to avoid transfusion
  • HIF-PHIs (roxadustat, daprodustat, vadadustat…): second line. Meta-analyses show no MACE excess vs ESA, but ESAs have longer safety data (KDOQI). Avoid with cancer, prior MI/stroke/VTE/access thrombosis, ADPKD, proliferative retinopathy, PAH, pregnancy. Never combine with an ESA. Roxadustat: monitor thyroid. Stop if no response by 3–4 months
  • Hyporesponsiveness → rework the causes. Consider a HIF-PHI trial. Anti-EPO pure red cell aplasia → stop the ESA and involve haematology
transplant candidates

Avoid transfusion where possible (HLA sensitisation lengthens the wait and harms graft outcomes). Use iron and ESA instead.


evidence

trialdesignresult
PIVOTAL (2019)2141 HD; proactive IV iron sucrose 400 mg/month (hold if ferritin >700 or TSAT ≥40%) vs reactiveMI/stroke/HF admission HR 0.80; less ESA use; no excess infection
TREAT (2009)darbepoetin to Hb 130 vs rescue, T2D + non-dialysis CKDno benefit on death/CV/kidney outcomes; more stroke
CHOIR (2006)epoetin to Hb 135 vs 113, non-dialysis CKDmore death/CV events in the high-target arm

adverse effects

  • ESA: hypertension, stroke, access thrombosis and VTE (worse at higher Hb), pure red cell aplasia (rare)
  • IV iron: infusion reactions mostly minor (Fishbane: flushing, myalgia, chest tightness, no hypotension/wheeze/stridor) → stop, observe, restart at 25–50% rate; no adrenaline or antihistamine. True anaphylaxis (hypotension, wheeze, stridor) → adrenaline 0.5 mg IM, fluids, oxygen, admit, no more IV iron → iron deficiency
  • Ferric carboxymaltose: hypophosphataemia (FGF-23-mediated) → osteomalacia with repeated doses
  • Oral iron: GI upset, constipation

Prepared 2026-11-01. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction ESAs and IV iron